<DOC>
	<DOC>NCT02660112</DOC>
	<brief_summary>This 24-week study will test the safety and effectiveness of synthetically produced (+) Epicatechin in treating patients who have Friedreich's Ataxia, a neurological disorder.</brief_summary>
	<brief_title>(+) Epicatechin to Treat Friedreich's Ataxia</brief_title>
	<detailed_description />
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<criteria>Confirmed diagnosis of Friedreich's Ataxia (FA) by Frataxin genetic testing and/or Frataxin enzyme analysis Between age 10 and 50 years of age, inclusive Body weight of 25 kilograms or higher Minimum of one affected organ (cardiac or neurological) system, as evidenced by clinical signs/symptoms Disease duration â‰¤7 years, based on onset date of FA symptoms Has no known contraindication to gadolinium contrast such as severe allergy or Glomerular Filtration Rate &lt;30 ml/min/m^2. Has no known contraindication to noncontrast Magnetic Resonance Imaging (MRI) evaluation such as pacemaker or magnetically active metal fragments. Women of childbearing age must: Have a negative pregnancy human chorionic gonadotropin test prior to receiving study drug. Agree to use contraception for the duration of the study drug dosing, plus 1 month after completion of the study. Advanced cardiac failure, New York Heart Association (NYHA) Classification ScaleClass IV (advanced stage heart failure) Clinically significant comorbidities that may also lead to cardiomyopathy, for example long standing hypertension, familial cardiomyopathy. Clinically significant comorbidities that would, in the opinion of the investigators, compromise the interpretation of test results. Pregnant, breastfeeding or planning to become pregnant during study timeframe. Patients with contraindications to regadenoson, i. e. second or thirddegree atrioventricular (AV) block or sinus node dysfunction. Has received an investigational drug within thirty (30) days of baseline visit. Thrombocytopenia (&lt;125 x 10^9/Liter) or prolonged Prothrombin Time/Partial Thromboplastin Time (PT/PTT) at baseline. Clinically significant hypotension (systolic blood pressure &lt;90) due to heart failure or other conditions.</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>